We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

73 hedge funds and large institutions have $205M invested in AEON Biopharma in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 6

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

3% more funds holding

Funds holding: 71 → 73 (+2)

1% more capital invested

Capital invested by funds: $202M → $205M (+$2.65M)

0.05% more ownership

Funds ownership: 1.04% → 1.09% (+0.05%)

Holders
73
Holders Change
+2
Holders Change %
+2.82%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
12
Reduced
6
Closed
6
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
+$6K

Top Buyers

Rank Fund Capital Flow
1
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$5.51M
2
UOC
UBS O'Connor
Illinois
+$5.13M
3
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$2.91M
4
FTCM
First Trust Capital Management
Illinois
+$2.45M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$2.29M

Top Sellers

Rank Fund Capital Flow
1
LA
Linden Advisors
New York
-$5.51M
2
Citadel Advisors
Citadel Advisors
Florida
-$4.89M
3
LOAMU
Lombard Odier Asset Management (USA)
New York
-$1.22M
4
JP Morgan Chase
JP Morgan Chase
New York
-$1.01M
5
AR
Advisory Research
Illinois
-$991K
Name Holding Trade Value Shares
Change 		Change in
Stake
ECP
1
Empyrean Capital Partners
California
$13.7M – – –
Marshall Wace
2
Marshall Wace
United Kingdom
$13M – – –
DKCM
3
Davidson Kempner Capital Management
New York
$12.4M – – –
HSBC Holdings
4
HSBC Holdings
United Kingdom
$10.8M – – –
AC
5
Aristeia Capital
Connecticut
$10.1M +$294K +417 +3%
RCM
6
Radcliffe Capital Management
Pennsylvania
$8.5M – – –
PC
7
Periscope Capital
Ontario, Canada
$8.06M +$491K +696 +6%
SCM
8
Shaolin Capital Management
Florida
$7.95M – – –
D.E. Shaw & Co
9
D.E. Shaw & Co
New York
$7.8M +$2.29M +3,248 +42%
Citadel Advisors
10
Citadel Advisors
Florida
$5.89M -$4.89M -6,927 -45%
LP
11
LMR Partners
United Kingdom
$5.89M – – –
Millennium Management
12
Millennium Management
New York
$5.55M -$24.7K -35 -0.4%
SCM
13
Saba Capital Management
New York
$5.39M +$294K +417 +6%
Hudson Bay Capital Management
14
Hudson Bay Capital Management
Connecticut
$5.3M – – –
UOC
15
UBS O'Connor
Illinois
$5.13M +$5.13M +7,264 New
CH
16
CVI Holdings
Delaware
$5.05M – – –
FTCM
17
Fir Tree Capital Management
New York
$4.96M – – –
TCM
18
Tenor Capital Management
New York
$4.9M – – –
KIM
19
Karpus Investment Management
New York
$4.78M – – –
SC
20
Sculptor Capital
New York
$4.7M – – –
PMAM
21
Picton Mahoney Asset Management
Ontario, Canada
$3.43M – – –
WA
22
Whitebox Advisors
Minnesota
$2.95M – – –
Parallax Volatility Advisers
23
Parallax Volatility Advisers
California
$2.91M +$2.91M +4,126 New
State of Wisconsin Investment Board
24
State of Wisconsin Investment Board
Wisconsin
$2.81M – – –
Goldman Sachs
25
Goldman Sachs
New York
$2.72M – – –
1
2 3 4

AEON Hedge Fund Activity: Q2 2022 in Review

73 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q2 2022, worth a combined $205M — up 1.3% from $202M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new AEON positions and 6 closed out — a net gain of 2 holders — while 12 added to existing stakes and 6 trimmed.

The largest buyer was Bank of Montreal, opening a new position worth an estimated $5.51M. The largest seller was Linden Advisors, cutting an estimated $5.51M.

  • 73 institutional investors held AEON Biopharma (AEON) as of Q2 2022, up from 71 in Q1 2022.
  • Funds reported $205M of AEON Biopharma stock for Q2 2022, up 1.3% quarter-over-quarter.
  • 8 funds opened new AEON Biopharma positions in Q2 2022 and 6 closed out, a net change of +2 holders.
  • The largest AEON Biopharma buyer in Q2 2022 was Bank of Montreal, an estimated $5.51M added.
  • The largest AEON Biopharma seller in Q2 2022 was Linden Advisors, an estimated $5.51M sold.

Based on aggregated 13F filings for Q2 2022.